Capra Biosciences lands $9.5M grant to onshore drug ingredient production

What's the deal? Capra Biosciences has received US$6.15M grant from the Administration for Strategic Preparedness and ResponseDealroom has a profile for this one. Try Dealroom →, part of the U.S. Department of Health and Human Services. The award brings Capra's total ASPR funding to approximately $17 million.

What it means. The Manassas, Virginia-based biomanufacturing company uses modular, continuous bioreactors to produce active pharmaceutical ingredients (APIs) domestically. Its initial $7.5 million ASPR award, announced in July 2024, supported validation of aspirin and acetaminophen production in under two years.

What's next? The new funding supports Capra's move towards cGMP production and regulatory filings, while expanding its API targets to seven. The company is continuing its work with X Development's A-Life teamDealroom has a profile for this one. Try Dealroom → and Next Rung TechnologyDealroom has a profile for this one. Try Dealroom →.

Read more: Chemical Engineering

Image credit: Generated with Gemini